- Active not recruitingPHASE1
A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma
This study looks at new drug combinations for advanced kidney cancer. We want to see how safe and effective MEDI5752 is when given with either Lenvatinib or Axitinib to people with this type of cancer.
For: Advanced Renal Cell CarcinomaUnited States · Australia · France - Not yet recruitingPHASE2
MEDI5752 in Patients With Mature Tertiary Lymphoid Structures Solid Tumors.
This study is testing a new treatment called MEDI5752 for advanced solid tumors. It's for people whose cancer has specific features and either haven't had immunotherapy before or it stopped working. The aim is to see how well MEDI5752 works.
For: Advanced Solid TumorFrance